CF
ZVRA icon

Corebridge Financial’s Zevra Therapeutics ZVRA Stock Holding History

Corebridge Financial’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-26,284
Closed -$197K – 2881
2025
Q1 		$197K Sell
26,284
-10
-0% -$79 ﹤0.01% 2095
2024
Q4 		$219K Buy
26,294
+3,801
+17% +$32.4K ﹤0.01% 2120
2024
Q3 		$156K Sell
22,493
-138
-0.6% -$937 ﹤0.01% 2361
2024
Q2 		$111K Buy
+22,631
New +$107K ﹤0.01% 2538

Other funds holding ZVRA

WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Corebridge Financial's ZVRA Position: Q2 2025 in Review

Corebridge Financial sold out of Zevra Therapeutics (ZVRA) in Q2 2025, closing a stake of 26,284 shares — an estimated $197K sold.

Corebridge Financial first reported a position in ZVRA in Q2 2024 and held it in 4 quarters. The position peaked at $219K in Q4 2024. 120 funds tracked by Wall St. Rank hold ZVRA as of Q2 2025.

  • Corebridge Financial reported no remaining Zevra Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 26,284 Zevra Therapeutics shares in Q2 2025, an estimated $197K.
  • Corebridge Financial first reported a position in Zevra Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Zevra Therapeutics position peaked at $219K in Q4 2024.
  • 120 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.